Etanercept can improve the symptoms of JIA: Scientific evidence suggests that etanercept can improve the symptoms of 74% of the patients. Health status and disease activity improved over a four year period, as the international and Hungarian database suggests. Etanercept treatment is the dominant strategy in JIA patients with an inadequate response or an intolerance to MTX
Further study and surveillance are warranted. Outcome and harm from therapy and disease, based on scientific evidence identified, was not measured beyond four year. Funders should consider the value of prospectively measuring the costs and impact of therapy on the general JIA population.